TrialHuman vaccines & immunotherapeutics2024

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines.

Camilo C Roa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.